Stockwinners Market Radar for March 24, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:39 EDT Ecopetrol not advancing in discussion on possible transactions - Ecopetrol "informs that, with regards to statements in the public media about a possible acquisition by Ecopetrol S.A. of the company Monomeros Colombo Venezolanos S.A., Ecopetrol warns the public that, within the framework of its 2040 strategy and business plan announced to the market, it is not advancing in discussions regarding possible transactions involving this company."

20:18 EDT Cathie Wood's ARK Investment bought 185.2K shares of Coinbase today

20:15 EDT Lockheed Martin awarded $186.5M U.S. Navy contract modification - Lockheed Martin is awarded a $186,511,034 modification to a cost-plus-fixed-fee order against a previously-issued basic ordering agreement. This modification adds scope to provide non-recurring engineering and test vehicle materials for the development of the Air-to-Ground Missile, Long-Range Anti-Ship Missile, C-3 variant in support of providing a combined Anti-Surface Warfare, LRASM, and Joint Air-to-Surface Standoff Missile strike capability for the Navy.

20:13 EDT BAE Systems, Scientific Research Corp awarded $536.7M U.S. Navy contract - BAE Systems Technology Solutions & Services and Scientific Research Corp are awarded a not-to-exceed $536,700,000 cost-plus-fixed-fee, cost-only, indefinite-delivery/indefinite-quantity multiple award contract for the procurement of engineering services that provide integration, test, and installation of command, control, communications, computers, and intelligence on surface ships.

18:02 EDT Aurora Cannabis announces Nasdaq notice of non-compliance - Aurora Cannabis announced receipt of a notification letter from The Nasdaq Stock Market dated March 24, advising that the company was not in compliance with Nasdaq Listing Rule 5450(a)(1) as the bid price of the company's listed securities had closed at less than $1.00 per share over the last 30 consecutive business days from February 8 to March 23. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the company has until September 20, being 180 calendar days from the date of the Notification Letter, to regain compliance with the Minimum Bid Price Requirement.

17:15 EDT Berkshire Grey trading resumes

16:48 EDT Berkshire Grey enters merger agreement with SoftBank Group - Berkshire Grey (BGRY) announced that the company has entered into a definitive merger agreement with SoftBank Group (SFTBY) and its affiliate. Under the agreement, SoftBank will acquire all of the outstanding capital stock of the company not currently owned by SoftBank for $1.40 per share in an all-cash transaction valued at approximately $375M. SoftBank, a strategic investment holding company with stakes in AI, smart robotics, IoT, telecommunications, internet services, and clean energy technology providers, has been an investor in Berkshire Grey since 2019. The agreement, which has been unanimously approved by Berkshire Grey's board of directors and represents a premium of approximately 24% to the closing stock price as of March 24, the last trading day prior to the date of this announcement. The transaction is not subject to a financing condition and is expected to close in the third quarter of 2023, subject to the satisfaction of customary closing conditions, including the approval of Berkshire Grey's stockholders and regulatory approvals.

16:37 EDT Eastern Company announces restructuring of COO position - The Eastern Company announced that Mark Hernandez, Eastern's President and CEO, has moved forward with the restructuring of the COO position. Hernandez has eliminated the position of COO and will assume the duties which were previously the responsibility of James Woidke, COO. Woidke's last day with the Eastern Company will be on March 31.

16:34 EDT NuCana: TBA of EPA rules European Patent 2955190 not valid - NuCana announced that, following a hearing on March 24, the Technical Board of Appeal of the European Patent Office issued an oral judgement that NuCana's European Patent 2955190 is not valid. The TBA reversed the previous decisions of the EPO's Examination Division which issued NuCana's '190 patent and of the EPO's Opposition Division which upheld this patent in 2021. In July 2022, the Regional Court of Dusseldorf issued a judgement that fully endorsed the decision of the EPO's Opposition Division. The TBA considered a part of Claim 1 of the '190 patent to lack an inventive step and did not allow NuCana to overcome this finding by an appropriate amendment of the claims in line with established case law of the EPO. "This aspect of the decision is particularly disappointing," said Dr. Thorsten Bausch, Senior Partner at Hoffmann Eitle, who represented NuCana at the hearing. This follows on from the judgement of the Patents Court of England and Wales handed down on March 21, 2023 which held that the '190 patent was invalid in the UK. Neither of these decisions affect the patent protection on any of NuCana's anti-cancer ProTides, which are covered by separate patents that were not involved in this litigation.

16:32 EDT Xoma receives adverse decision in arbitration with licensee - In a regulatory filing, Xoma said, "In June 2021, XOMA Corporation initiated a binding arbitration proceeding with one of our licensees at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under our license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, we received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award us damages and ruled that the license agreement has expired. The panel ruled that we are responsible for the Licensee's costs as well as arbitrators' and administrative fees previously incurred by the Licensee, which are estimated to be approximately $4 million. In addition, we may be responsible for certain additional arbitrators' and administrative fees to be determined in a final accounting."

16:30 EDT Dogness receives Nasdaq notification regarding minimum bid requirements - Dogness announced that on March 23, 2023, it received a letter from The Nasdaq Stock Market LLC, notifying the company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the company's Class A common shares was below $1.00 per share for 30 consecutive trading days. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the company's Class A common shares, which will continue to trade uninterrupted on Nasdaq under the ticker "DOGZ".

16:17 EDT Star Group adopts Unitholder Rights Plan - Star Group announced that it has adopted a Unitholder Rights Plan. The Plan is similar to plans adopted by other public companies and is intended to protect the interests of the company and all unitholders by reducing the likelihood that any entity, person or group gains control of the company through open-market accumulation or other means without payment of an adequate control premium. The Plan also helps ensure that the Board has sufficient time to make informed, deliberate decisions that are in the best interests of the company and all unitholders. The Plan has not been adopted in response to any specific takeover bid or other proposal to acquire control of the company and is not intended to deter offers that are fair and otherwise in the best interests of all unitholders. In accordance with the Plan, the General Partner of the company has authorized and declared a distribution of one unit purchase right on each outstanding Common Unit and General Partner Unit of the company as of the close of business on April 4, with each Right representing the right to purchase one Common Unit on the terms and conditions of the Plan. Under the Plan, the Rights will initially trade together with Star's Common Units and will not be exercisable until the occurrence of certain events relating to the acquisition of 15% or more of the outstanding common units by a person, entity or group in a transaction not approved by the Board. The Rights will expire on March 24, 2028 unless earlier redeemed, exchanged or amended by the General Partner. If a person, entity or group beneficially owns 15% or more of the outstanding Common Units prior to the company's announcement of its adoption of the Plan, then that person's, entity's or group's existing ownership percentage will be grandfathered, although the rights will become exercisable if at any time after the announcement of the adoption of the Plan such person, entity or group increases its ownership of Common Units by more than 0.1% of the outstanding Common Units.

16:02 EDT Iovance Biotherapeutics completes BLA submission for lifileucel - Iovance Biotherapeutics announced it has completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration for lifileucel. Lifileucel is a tumor infiltrating lymphocyte therapy intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "Completing our BLA submission for lifileucel is a critical step forward in our journey to deliver the first individualized, one-time cell therapy for a solid tumor. I would like to acknowledge the patients and physicians who participated in the C-144-01 clinical trial and the FDA review team for their commitment and support, as well as our internal team for their tremendous effort in completing the first BLA submission for Iovance. Our preparations for commercialization remain on track to support a launch later this year. We look forward to continued collaboration with the FDA as they review this new class of treatment for advanced melanoma patients with limited options."

16:00 EDT BridgeBio Pharma trading resumes

15:54 EDT BridgeBio Pharma trading halted, volatility trading pause

14:44 EDT Pharming up 22% after resuming trading following announcement of FDA approval - Shares of Pharming are up $2.45, or 22%, to $13.73 after the company announced that the Food and Drug Administration has approved Joenja for the treatment of activated phosphoinositide 3-kinase delta syndrome, or APDS, in adult and pediatric patients 12 years of age and older.

14:31 EDT Pharming up 7% after FDA approves Joenja for APDS

14:31 EDT PharmaNetics, Inc. trading halted, volatility trading pause

13:01 EDT Baker Hughes reports U.S. rig count up 4 to 758 rigs

12:14 EDT Luminar addresses 'misconceptions with facts,' says ASPs 'not theoretical' - In a letter to shareholders, Luminar CFO Tom Fennimore said: "Luminar has established itself as the clear leader in the industry; in 2023 this leadership position has widened with expanded wins, now totaling 20+ vehicle lines. This success has been met with increased noise, but has no effect on the fundamental value of Luminar. We have more conviction than ever in our near and long-term value creation opportunity. Questions were raised this week about our pricing forecast. Our ASP's are not theoretical and are supported by our awarded contracts that span the decade. There is additional upside to further grow revenue per vehicle with our software and insurance solutions." Fennimore said that the company expects "this spread of misinformation to continue as our success grows and their struggles accelerate." Reference Link

12:00 EDT Getty Images falls -9.0% - Getty Images is down -9.0%, or -36c to $3.67.

12:00 EDT Steelcase rises 6.0% - Steelcase is up 6.0%, or 46c to $8.06.

12:00 EDT Braskem rises 8.3% - Braskem is up 8.3%, or 52c to $6.81.

11:51 EDT Maxpro Capital Acquisition Corp trading halted, volatility trading pause

11:24 EDT User reports indicate problems at Amazon says Downdetector - Reference Link

10:19 EDT Verde Clean Fuels Inc trading halted, volatility trading pause

10:00 EDT Deutsche Bank falls -6.7% - Deutsche Bank is down -6.7%, or -65c to $9.00.

10:00 EDT Oxford Industries falls -12.0% - Oxford Industries is down -12.0%, or -$14.02 to $102.45.

10:00 EDT Sunlands Online rises 6.3% - Sunlands Online is up 6.3%, or 57c to $9.64.

09:51 EDT Assure Holdings regains compliance with Nasdaq continued listing requirements - Assure Holdings announced that the company has received confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. On October 11, 2022, Staff notified the company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On March 20, 2023, Staff notified the company that for the last 10 consecutive business days, from March 6 to March 17, 2023, the closing bid price of the company's common stock has been at $1.00 per share or greater. Accordingly, Staff concurrently determined that the company has regained compliance with Listing Rule 5550(a)(2) and has deemed this matter closed.

09:47 EDT American Realty Investors falls -7.0% - American Realty Investors is down -7.0%, or -$1.96 to $25.92.

09:47 EDT Direxion Financial Bear 3x rises 4.3% - Direxion Financial Bear 3x is up 4.3%, or $1.04 to $25.47.

09:47 EDT Amprius Technologies rises 6.8% - Amprius Technologies is up 6.8%, or 52c to $8.17.

09:44 EDT DiamondHead Holdings Corp trading resumes

09:35 EDT JATT Acquisition Corp trading halted, volatility trading pause

09:17 EDT Las Vegas Palms Casino selects Rekor Systems roadway intelligence solution - Rekor Systems announced that the Palms Casino Resort has purchased a multi-year contract for Rekor's AI-powered platform for intelligence-led public safety, Rekor Scout as well as a number of Edge Max systems, Rekor's vehicle and license plate recognition systems, as a key part of the resort casino's new plans to enhance property security as well as guest safety while also better understanding vehicle traffic.

09:08 EDT Novo Integrated Sciences provides update on certain current actions, events - Novo Integrated Sciences provides an update with respect to certain actions and events, as follows: As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement with SwagCheck and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of SWAG's outstanding shares. SWAG holds a specific right of purchase of a precious gem collection as provided for in an agreement between SWAG and a Court-appointed Successor Receiver for the United States District Court for the Central District of California. Pursuant to the terms of the SWAG Agreement, as amended, the SWAG Agreement was to close no later than January 10, 2023. Although the SWAG Agreement has not yet closed, the parties continue to work together with the intention of closing the transaction. As previously reported, on December 15, 2022 and January 25, 2023, the Company was notified that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) because it had not filed its Form 10-K for the year ended August 31, 2022 and its Form 10-Q for the period ended November 30, 2022 respectively. On February 17, 2023 and March 22, 2023, based on Nasdaq's further review, Nasdaq granted an exception to enable the Company to regain compliance with the Rule. As of March 23, 2023, the principal balance owed by the Company pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to CVI Investments, Inc. is $0.00, the principal balance owed by the Company pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to Hudson Bay Master Fund Ltd is $50,000, and the principal balance owed by the Company pursuant to the secured convertible promissory note, dated as of November 17, 2021, issued by the Company to Jefferson Street Capital LLC is $0.00.

09:06 EDT Recruiter.com, Job Mobz enter strategic partnership for OnDemand solutions - Recruiter.com Group has teamed up with Job Mobz to deliver enterprise OnDemand solutions and services. The strategic sales and delivery partnership between Recruiter.com and Job Mobz will allow Recruiter.com to leverage Job Mobz's expertise and create more operating leverage in its business. As part of the partnership, Recruiter.com will transition certain Recruiter on Demand clients and staff to Job Mobz in exchange for an ongoing revenue stream. The revenue stream will be derived from a fixed percentage of sales on the book of business and a revenue share on referred business.

08:36 EDT BioSig Technologies appoints Lorraine Spurge to Advisory Board - BioSig Technologies announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory Board. As founder and CEO of Maple Stone Capital Advisors, Ms. Spurge began her 40-year financial career with Drexel Burnham Lambert.

08:34 EDT Connexa Sports Technologies receives notice of non-compliance from Nasdaq - Connexa Sports Technologies received a letter from The Nasdaq Stock Market on March 21, 2023 notifying the Company that it is not in compliance with the periodic filing requirements for continued listing because the Company's Form 10-Q for the fiscal quarter ended January 31, 2023 was not filed with the Securities and Exchange Commission by the required due date of March 17, 2023, which is an additional basis for delisting the Company's securities from the Nasdaq and indicating that the Nasdaq Hearings Panel will consider this matter in rendering a determination regarding the Company's continued listing on the Nasdaq at its hearing before the Panel scheduled for Thursday, March 30, 2023. On February 21, 2023, the Company had previously announced that it received a letter from the Nasdaq on February 14 2023, indicating that, due to the Company's failure, in violation of Listing Rule 5250(c)(1), to file its Annual Report on Form 10-K with respect to the fiscal year ended April 30, 2022 and Quarterly Reports on Form 10-Q for the periods ended July 31, 2022 and October 31, 2022, by February 13, 2023, absent the submission of a timely appeal by February 21, 2023, trading of the Company's common stock would be suspended from The Nasdaq Capital Market at the opening of business on February 23, 2023. Nasdaq would also have filed a Form 25-NSE with the SEC, which would have resulted in the removal of the Company's securities from listing and registration on The Nasdaq Stock Market. Additionally, as previously disclosed, on January 12, 2023, Nasdaq notified the Company that due to the resignations from the Company's board, audit committee and compensation committee on November 17, 2022, the Company no longer complies with Nasdaq's independent director, audit committee and compensation committee requirements as set forth in Listing Rule 5605. The Company timely submitted its plan of compliance with respect to the Corporate Governance Deficiencies by February 27, 2023 as required by the Nasdaq. However, pursuant to Listing Rule 5810(c)(2)(A), the Corporate Governance Deficiencies serve as additional and separate basis for delisting and the Company will be required to address these concerns before the Panel when it appeals the Staff Determination. On February 21, 2023, appealed the Staff Determination to the Panel, and requested that the stay of delisting, which otherwise would expire on March 8, 2023, pursuant to Listing Rule 5815(a)(1)(B), be extended until the Panel issued a final decision on the matter. The Nasdaq granted the Company's request to extend the stay, pending the Hearing, and a final determination regarding the Company's listing status. The Company is required to address the Additional Delinquency, the Delinquent Filings, and the Corporate Governance Deficiencies before the Panel. If the Company's appeal is denied or the Company fails to timely regain compliance with Nasdaq's continued listing standards, the Company's common stock will be subject to delisting on the Nasdaq. Although the Company is working diligently to file the Delinquent Filings, there can be no assurance that they will be filed prior to the Hearing.

08:33 EDT Bit Digital announces investment in Auros Global Limited - Bit Digital is pleased to announce a strategic investment in Auros Global Limited. Auros is a crypto-native algorithmic trading and market making firm that delivers best-in-class liquidity for exchanges and token projects. This strategic investment advances Bit Digital's goal to maximize risk-adjusted returns of its digital assets, while protecting its business against operational and treasury risks to ensure healthy and consistent cash flows. Bit Digital intends to utilize Auros' suite of derivatives offerings to provide both hedging and yield opportunities for a portion of its digital asset holdings.

08:21 EDT Impel Pharmaceuticals sees Trudhesa delivering 80K-110K TRx for 2023 - The Company projects Trudhesa will deliver prescriptions within the range of 80,000 - 110,000 TRx for full year 2023.

08:19 EDT CMA 'narrows scope of concerns' in Microsoft-Activision review - The U.K. Competition and Markets Authority, or CMA, announced: "The CMA has received a significant amount of new evidence in response to its original provisional findings. Having considered this new evidence carefully, together with the wide range of information gathered before those provisional findings were issued, the CMA inquiry group has updated its provisional findings and reached the provisional conclusion that, overall, the transaction will not result in a substantial lessening of competition in relation to console gaming in the UK. The most significant new evidence provided to the CMA relates to Microsoft's financial incentives to make Activision's games, including Call of Duty (CoD), exclusive to its own consoles. While the CMA's original analysis indicated that this strategy would be profitable under most scenarios, new data (which provides better insight into the actual purchasing behaviour of CoD gamers) indicates that this strategy would be significantly loss-making under any plausible scenario. On this basis, the updated analysis now shows that it would not be commercially beneficial to Microsoft to make CoD exclusive to Xbox following the deal, but that Microsoft will instead still have the incentive to continue to make the game available on PlayStation. The CMA's addendum to its provisional findings today relates only to competition in the supply of consoles and not to competition in the supply of cloud gaming services, where the CMA is continuing to carefully consider the responses provided in relation to the original provisional findings. The CMA's merger investigation continues, and it remains due to issue its final report by 26 April 2023." Reference Link

08:14 EDT Midatech Pharma announces results of general meeting - At the General Meeting, Shareholders approved, inter alia, the Share Consolidation, as detailed in the Circular. The Share Consolidation consists of a consolidation of the ordinary shares of GBP 0.001 each in the capital of the Company, such that every 20 Ordinary Shares will be consolidated into one new ordinary share of GBP 0.02 nominal value each. Following the Share Consolidation, the Company will have a single class of ordinary shares of GBP 0.02 each in issue, being the Consolidated Ordinary Shares. Also effective on or around 27 March 2023, the ratio of the Company's American Depositary Shares will change from one ADS representing 25 Ordinary Shares to one ADS representing five Consolidated Ordinary Shares, with new CUSIP 59564R609. No fractional ADSs will be allocated. The aggregate fractional ADSs, if any, will be sold and the net proceeds will be distributed to the entitled ADS holder. The Company's depositary, The Bank of New York Mellon, will contact ADS holders and arrange for the exchange of their existing ADSs for new ADSs. Application has been made to the London Stock Exchange plc for the admission to trading on AIM of the Consolidated Ordinary Shares, which is expected to become effective and dealings commence at 8.00 a.m. on or around 27 March 2023. Following approval by Shareholders of the relevant resolution, Midatech's name will be changed to Biodexa Pharmaceuticals PLC on or around 27 March 2023. The new AIM Symbol/TIDM will be "BDRX" once the name change is effected, and the new trading symbol on NASDAQ is expected to also be "BDRX". Further to today's approval by Shareholders, the admission of the Ordinary Shares to trading on AIM will be cancelled, although trading on NASDAQ in the ADSs will be maintained. The AIM Cancellation is expected to take place approximately one month following today's General Meeting, on 26 April 2023, in order to give Shareholders sufficient time to convert their Consolidated Ordinary Shares into ADSs, should they wish to do so. Shareholders are recommended to refer to the Circular and the 'Frequently Asked Questions' document that accompanied the Circular, which is available on the Company's website and addresses further questions in respect of the implications of the AIM Cancellation in relation to holdings of Consolidated Ordinary Shares. In order to facilitate the Company's sole remaining listing on NASDAQ, the Company will adopt New Articles with effect from the AIM Cancellation, which were also approved at today's General Meeting.

08:09 EDT Rocket Lab successfully launches 35th Electron rocket - Rocket Lab USA (RKLB) announced it has successfully launched its 35th Electron rocket, deploying two multi-spectral Gen-2 satellites to low Earth orbit for BlackSky (BKSY) through launch services provider Spaceflight, Inc. The mission took place just seven days following the Company's previous Electron mission from Launch Complex 2 in Virginia, setting a new company record for fastest turnaround between Electron missions.

08:05 EDT Curaleaf to delay Q4, FY earnings release, conference call - Curaleaf Holdings announced that it will delay its fourth quarter and full year earnings release and conference call, which were originally scheduled for March 28. Due to the complexities of converting three years of financials from IFRS to U.S. GAAP coinciding with year and quarter-end reporting, and the review of the treatment of various accounting matters, the company requires additional time to complete its financial statements. The company expects to file its financial statements within the month of April, no later than the prescribed filing deadline provided for under applicable securities laws. The company will announce the date of the release of its financial statements and an earnings conference call in a subsequent press release.

08:03 EDT Biocept announces enrollment of first patient in FORSEE trial - Biocept announces enrollment of the first patient in the FORESEE clinical trial with the Company's proprietary cerebrospinal fluid assay CNSide. The FORESEE trial is a multicenter, prospective clinical trial expected to enroll 40 patients with breast or non-small cell lung cancer who have suspicious or confirmed leptomeningeal metastases. The goal of the FORESEE trial is to evaluate the performance of CNSide in monitoring the LM's response to treatment and to assess the impact of CNSide on treatment decisions made by physicians. This first patient was seen at the UT Southwestern Medical Center, one of the largest and most respected hospitals in the nation. "The enrollment of the first patient in the FORESEE clinical study is a major milestone for the management of patients with leptomeningeal disease," said Michael Youssef, MD, Assistant Professor in the Department of Neurology and the Department of Hematology and Oncology at UT Southwestern Medical Center. "We are excited to be at the forefront of this innovation, which will greatly benefit patients."

08:02 EDT authID appoints Rhon Daguro as CEO, Joe Trelin as chairman of the board - authID announced the appointment of Rhon Daguro as CEO and Joe Trelin as Chairman of the Board. Rhon served most recently as the Chief Revenue Officer of Socure Inc. Having joined the authID Board of Directors in April 2022, Joe Trelin, assumes the role of Chairman, effective immediately. Joe offers industry expertise having formerly served as the Chief Platform Officer at CLEAR.

08:01 EDT US Foods appoints Iacobucci as SEVP, Field Operations, CCO - US Foods Holding announced that Andrew Iacobucci is appointed Senior Executive Vice President, SEVP, Field Operations and Chief Commercial Officer, CCO, effective today. In his new role, Iacobucci will oversee the company's local sales, commercial excellence, merchandising, marketing, CHEF'STORE, US Foods Direct and MOXe teams and have P&L responsibility for the company's broadline business. He will report to Dave Flitman, Chief Executive Officer, as a member of the company's Executive Leadership Team. Iacobucci joined US Foods in 2017 and most recently served as Chief Transition Officer, advising and supporting Flitman as he onboarded.

07:36 EDT Cryptyde provides operational, business update on Forever 8 - Cryptyde provided its investors a corporate update on its subsidiary, Forever 8 Fund. The company said, "As F8 begins to scale its customer count, it continues to invest in both its customer facing and internal portfolio and customer management technologies. During the last 6 months, F8 has rolled out proprietary features that enhance its customers' inventory management experience. Some of these features include giving customers the ability to leverage F8's demand forecasting algorithms to optimize their inventory levels and streamline the purchase order process. At the same time, F8 also provides tracking of supply chain data to identify areas where customers may have lost inventory. F8 is connected to an increasingly wide range of selling platforms, as it continually expands its data coverage across the supply chain. It is leveraging these large data sets to advance its due diligence and onboarding tools. This includes modeling SKUs through profitability, market, sales trends, platform shifts, and other risk profiles faced by eCommerce sellers. Over the course of this year, F8 will be releasing these internal features to customers to provide them with insights on the optimum management of the SKU portfolio of their companies. F8 is expanding its partnership with Arca One, a 3PL with operations in Asia and the United States. Arca is currently expanding its operations as it moves into a new facility in San Bernardino, California, which will facilitate F8's anticipated growth. Since 2022, Arca has been instrumental in assisting F8's logistics and fulfillment requirements. F8 has spent over 2 years developing and refining its proprietary customer acquisition tool and continues to invest in and refine its capabilities. F8 believes it is positioned to identify new customers in an efficient and low-cost manner. In addition to this, F8 continues to grow organically by providing services for additional products from its existing customer base." "We continue to be pleased with the progress we have made with Forever 8 since its acquisition. We have projected revenue for Cryptyde of over $60 million in revenue for 2023 and remain confident that our business model is not only unique, but sustainable," said Brian McFadden, CEO of Cryptyde. "Furthermore, our commitment to shareholders is to use the capital invested in us very efficiently, both today and in how we fund our future expansions to support demand. We are engaged with clients and will judicially explore all options that are the most logical for our shareholders and our business,"

07:33 EDT Irwin Naturals releases CBD 25mg Softgels in Canada - Irwin Naturals announced the release of Irwin Naturals Cannabis' new CBD 25mg Softgels in Canada, available nationwide through the Starseed Medicinal Medical Group platform. CBD 25mg Softgels are just the first of five CBD and THC products that Irwin Naturals Cannabis, through its licensing agreement with Entourage Health Corp., plans to launch nationwide in Canada over the next few months. The company's product lineup will include a range of CBD and THC products designed in a variety of formulations to suit consumers' varying needs.

07:32 EDT PTC Therapeutics CEO Stuart Peltz to retire, Matthew Klein to succeed - Stuart Peltz, Ph.D., founding CEO of PTC Therapeutics announced that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Matthew Klein, M.D., M.S., F.A.C.S., current COO, has been named the company's CEO and will join the Board of Directors. The transition is effective immediately. Dr. Peltz will serve as a Senior Consultant to the company and join its Scientific Advisory Board following his retirement. Prior to joining PTC in 2019, Dr. Klein was CEO and Chief Medical Officer at BioElectron Technology, a biotechnology company focused on the development of redox-active small molecules for mitochondrial disease and related disorders of oxidative stress. PTC acquired BioElectron's assets in 2019.

07:17 EDT Mexican regulator approves Pan American's arrangement with Yamana, Agnico - Pan American Silver Corp. (PAAS) and Yamana Gold (AUY) provides an update on the status of Pan American's proposed acquisition of all of the issued and outstanding common shares of Yamana, following the sale by Yamana of its Canadian assets, including certain subsidiaries and partnerships which hold Yamana's interests in the Canadian Malartic mine, to Agnico Eagle Mines (AEM), all by way of a plan of arrangement under the Canada Business Corporations Act. On March 23, 2023, the Mexican Federal Economic Competition Commission approved the Arrangement. All required regulatory, shareholder and court approvals, including the final court order, have now been received and the Arrangement is anticipated to be completed on or about March 31, 2023. In addition, Pan American has declared a cash dividend of $0.10 per common share, payable on or about May 12, 2023, to holders of record of Pan American's common shares as of the close of markets on April 14, 2023. The dividends are eligible dividends for Canadian income tax purposes.

07:12 EDT 23andMe pilots program to raise awareness about Lipoprotein(a) - In support of Lipoprotein(a) Awareness Day, 23andMe Holding (ME) announced a collaboration with Novartis Pharmaceuticals Corporation (NVS) to increase awareness for Lipoprotein(a). High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions. The level of Lp(a), which can be detected through a simple blood test, is almost entirely determined by genes and is unrelated to diet, exercise or obesity, creating the need for greater awareness. With support from Novartis, 23andMe is piloting a new program to educate its customers about the risks associated with high Lp(a). 23andMe customers will be able to purchase a confidential screening test for Lp(a) and will be provided the option to connect with clinicians through 23andMe's telehealth service, Lemonaid Health.

07:10 EDT Pan American arrangement with Yamana, Agnico Eagle approved by Mexican FECC - Pan American Silver (PAAS) and Yamana Gold (AUY) provide an update on the status of Pan American's proposed acquisition of all of the issued and outstanding common shares of Yamana, following the sale by Yamana of its Canadian assets, including certain subsidiaries and partnerships which hold Yamana's interests in the Canadian Malartic mine, to Agnico Eagle Mines (AEM), all by way of a plan of arrangement under the Canada Business Corporations Act. On March 23, 2023, the Mexican Federal Economic Competition Commission, FECC, approved the Arrangement. All required regulatory, shareholder and court approvals, including the final court order, have now been received and the Arrangement is anticipated to be completed on or about March 31, 2023.

07:08 EDT Aslan Pharmaceuticals announces anticipated milestones - New clinical and translational data on eblasakimab will be presented at the ISID Meeting in Tokyo, Japan. Posters will be available to view at the meeting on May 10, 2023, and will be uploaded to ASLAN's website at this link following presentation. The first patient is expected to be enrolled in the farudodstat proof-of-concept Phase 2a study in AA in the second quarter of 2023. Topline data from the Phase 2b TREK-AD trial of eblasakimab is expected in early July 2023. Topline data from the TREK-DX trial of eblasakimab is expected in the first quarter of 2024. Topline interim data from the farudodstat Phase 2a study in AA is expected in the first quarter of 2024.

07:07 EDT Charge Enterprises, Eaton announce strategic collaboration - Charge Enterprises (CRGE) and Eaton (ETN) announced a strategic collaboration to fast-track electric vehicle, EV, charging infrastructure deployment for fleets and car dealers. Eaton and Charge are providing complete EV charging infrastructure for fleet electrification, including projects incorporating renewables and enabling net zero models. "Working closely with Eaton, we're offering a premier solution for fleets. Eaton is delivering intelligent and innovative electrical solutions for affordable and sustainable EV charging, while Charge integrates years of vehicle expertise and premium services to develop, plan and create fleet models that support Total Cost of Ownership TCO and maximize EV uptime as well as provide remote maintenance and monitoring," said Mark LaNeve, President of Charge. "Furthermore, our collective focus on safety, reliability and scalability only strengthens the solution delivered to the client," said LaNeve. Charge and Eaton will supply integrated charging infrastructure including the hardware, software, services, training, maintenance, as well as support for onsite renewables and energy storage systems.

07:04 EDT Oncorus expects cash to fund expenditures into early 2024 - Cash, cash equivalents and investments totaled $62.2 million as of December 31, 2022 compared to $123.9 million as of December 31, 2021.

07:02 EDT Humacyte expects cash to fund operations through 2024 - The Company reported cash, cash equivalents and short-term investments of $151.9 million as of December 31, 2022, compared to $225.5 million as of December 31, 2021. The $73.6 million net use of cash, cash equivalents and short-term investments for the year ended December 31, 2022 resulted from spending related to net operating activities for the period, including clinical and earlier-stage research and development programs, and preparation for the Company's anticipated commercial launch. The Company believes that its cash, cash equivalents and short-term investments are adequate to fund operations through the end of 2024, past the Company's current expected timelines for potential approval of the HAV in its vascular trauma indication.

06:45 EDT Ford says 'on track' with construction at BlueOval City mega-campus - Ford announces it is on track with construction at BlueOval City mega-campus and says in a press release it is "poised to usher in a new era of American innovation and manufacturing." Ford said: The electric vehicle and battery manufacturing campus in West Tennessee begins production in 2025, and will be home to Ford's second-generation electric truck, code named Project T3, and will be capable of producing 500,000 EV trucks a year at full production. Ford and partner SK On are investing $5.6 billion in the campus and creating approximately 6,000 new jobs. Ford has launched a comprehensive education and training effort called BlueOval Learning to prepare future employees. BlueOval City is designed to be Ford's first carbon neutral vehicle manufacturing and battery campus as Ford works to power all Ford plants globally with renewable and carbon-free electricity by 2035."

06:36 EDT GSK 'respectfully disagrees' with Zantac litigation ruling in California - In response to yesterday's Sargon ruling by the California state court in respect of the Goetz case, GSK plc issued the following statement: "GSK respectfully disagrees with this ruling by the California state court. Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. The litigation is still at an early stage and yesterday's decision relates only to the question of whether the plaintiff's experts can testify at trial in the Goetz case. It does not mean that the Court agrees with plaintiff's experts' scientific conclusions or their litigation-driven science. GSK will press additional defences and the plaintiff still needs to prove his case at trial. This ruling does not affect other state cases or the December 2022 Daubert ruling made in the federal Multi-District Litigation."

06:33 EDT Mitsubishi Materials makes strategic investment in Western Copper - Western Copper and Gold Corporation (WRN) announces a strategic equity investment by Mitsubishi Materials Corporation to further advance the Company's copper-gold Casino Project in the Yukon. Mitsubishi Materials has agreed to acquire that number of common shares of the Company that will represent approximately 5.0% of Western's issued and outstanding Shares, on an undiluted basis, following completion of the investment, at a price of C$2.63 per Share. The exact number of Shares to be issued, and proceeds to be received, by the Company will depend on whether Rio Tinto Canada (RIO) elects to exercise its pre-existing right to participate on a pro rata basis in equity financings by the Company to maintain its current ownership interest, which based on public filings is approximately 7.84%. Assuming Rio Tinto elects to exercise its participation right in full, then it is expected that 8,091,390 Shares will be issued to Mitsubishi Materials for aggregate gross proceeds of C$21.3 million and 878,809 Shares will be issued to Rio Tinto for aggregate gross proceeds of C$2.3 million. Western remains the sole owner of the Casino Project and will continue to be the operator. The Company will use the proceeds of the strategic investment to advance the project and to fund specific areas of study, developed with input from Mitsubishi Materials, with the aim of progressing to a development phase for the Casino Project. In connection with the strategic investment by Mitsubishi Materials, the Company and Mitsubishi Materials will enter into an investor rights agreement whereby, subject to certain conditions, Mitsubishi Materials will have certain rights until the earlier of its ownership falling below 3.0%, and the date that is 24 months following completion of the investment, including: the right to appoint one member to a Casino Project Technical and Sustainability Committee; the right to appoint the greater of one director of the Company or 17% of the number of directors, if Mitsubishi Materials' ownership increases to at least 12.5%. In addition, until the Expiry Date, Mitsubishi Materials will have a right to participate in future equity issuances to maintain its ownership in the Company and, in the event its ownership increases to 8.0%, will be provided with a one-time "demand registration right" and "piggy-back registration rights." Under the investor rights agreement, for a period of 24 months, Mitsubishi Materials will agree: not to sell, transfer, offer or otherwise dispose of any Shares without first notifying the Company; to abstain from voting or vote any Shares in favor of each director nominated by the board of directors of the Company for election by shareholders; not to acquire any securities of the Company, subject to certain exceptions. Mitsubishi Materials will have the right of first negotiation, until the later of its ownership falling below 3.0%, and the date that is 24 months following completion of the investment, to offtake at least its proportionate share of minerals produced from the Casino Project. The Company and Mitsubishi Materials will negotiate in good faith new rights and restrictions attaching to its share ownership on the earlier of 18 months following completion of the investment, and Mitsubishi Materials' ownership reaching 12.5% or greater. The closing of the strategic investment is expected to occur on or about April 14, 2023 and is subject to regulatory approval, including that of the Toronto Stock Exchange and the NYSE American LLC. The Shares will be subject to a statutory hold period in accordance with applicable securities legislation.

06:01 EDT Allarity announces reverse stock split - Allarity Therapeutics announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post split share for every 35 pre-split shares. The reverse stock split will become effective at 4:05 p.m. New York Time on Friday, March 24. The company's common stock will continue to trade on the Nasdaq Global Market under the existing trading symbol "ALLR" and will begin trading on a post split-adjusted basis when the market opens on Monday, March 27. The CUSIP number for Allarity's common stock following the reverse stock split will be 016744203.

05:54 EDT Interactive Brokers expected to raise rates on instantly available cash balances - Interactive Brokers announced that clients are expected to earn up to 4.33% on instantly available cash balances over $10,000. Unlike brokerages that offer significantly lower rates, Interactive Brokers conveniently pays interest directly to client brokerage accounts. This eliminates the need for separate sweeps accounts, funds or programs and enables cash to be instantly available. While interest rates available at other brokerages are only 0.01% - 2.32%, the market interest paid by Interactive Brokers, is calculated using the Fed Funds rate as the reference rate for minus 0.5%. As a result, if interest rates continue to rise as expected, clients of Interactive Brokers will have the opportunity to earn more.